Advantages of Technology Platform
Youngen has developed a Fast Integrated Screening Technology called FlSTsiran that is uniquely positioned to rapidly identify RNA molecules with potent activity, long durability and superior safety.
Youngen has developed a Multi-targeted Single-entity Technology called MSTsiran that is capable of incorporating two or more different siRNAs. This technology could be applied to treat many complex diseases that are caused by the dysregulation of more than one gene or multiple diseases.
Youngen has developed a siRNA Transport Technology called STTsiran that can significantly enhance the activity of siRNA drugs in extra-hepatic tissues. This technology enables tissue specific targeting including the brain, muscle, and adipose.
For more information about innovation and technology industry and new innovation of science , please feel free to contact us!
Youngen has been dedicated to bringing RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general, impacting millions of people and families around the world. Leveraging cutting-edge technological platforms, we build globally competitive diversified product pipelines with first-in-class and best-in-class potentials. We're exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders.
You must be logged in to post a comment.